First Time Loading...

CStone Pharmaceuticals
HKEX:2616

Watchlist Manager
CStone Pharmaceuticals Logo
CStone Pharmaceuticals
HKEX:2616
Watchlist
Price: 1.1 HKD 1.85% Market Closed
Updated: May 7, 2024

CStone Pharmaceuticals
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CStone Pharmaceuticals
Operating Income Peer Comparison

Comparables:
6160
1801
603392
300122
300896

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
CStone Pharmaceuticals
HKEX:2616
Operating Income
-¥508.2m
CAGR 3-Years
22%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Operating Income
-¥12B
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Operating Income
-¥1.1B
CAGR 3-Years
-36%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Operating Income
¥1.4B
CAGR 3-Years
22%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Operating Income
¥9.9B
CAGR 3-Years
38%
CAGR 5-Years
46%
CAGR 10-Years
47%
Imeik Technology Development Co Ltd
SZSE:300896
Operating Income
¥1.4B
CAGR 3-Years
59%
CAGR 5-Years
72%
CAGR 10-Years
N/A

See Also

What is CStone Pharmaceuticals's Operating Income?
Operating Income
-508.2m CNY

Based on the financial report for Dec 31, 2023, CStone Pharmaceuticals's Operating Income amounts to -508.2m CNY.

What is CStone Pharmaceuticals's Operating Income growth rate?
Operating Income CAGR 5Y
13%

Over the last year, the Operating Income growth was 42%. The average annual Operating Income growth rates for CStone Pharmaceuticals have been 22% over the past three years , 13% over the past five years .